e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 9

Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer

Joanna M Porter; Cici Jin; Michael Churchman; Ian Croy; C. Gourley; Oni Glyn-Wright; Marianne C. Stewart; Elizabeth Brownsell · 2025 · European Journal of Cancer

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: Antibody-drug conjugates (ADCs) are emerging anti-cancer agents. The folate receptor alpha (FOLRα)-directed ADC mirvetuximab soravtansine recently demonstrated clinical activity in platinum-resistant ovarian cancer, with other ADCs currently in development. The relative expression of FOLRα and other ADC targets is largely unknown across ovarian cancer histotypes. METHODS: Expression levels of the ADC targets FOLRα, TROP2 and B7-H4 were assessed by immunohistochemistry in patient cohorts using tumour tissue microarrays of the major ovarian cancer histotypes: high grade serous (HGSOC

Abstract by Joanna M Porter; Cici Jin; Michael Churchman; Ian Croy; C. Gourley; Oni Glyn-Wright; Marianne C. Stewart; Elizabeth Brownsell, European Journal of Cancer (2025) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1016/j.ejca.2025.115522